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A B S T R A C T
Purpose: To determine the efﬁcacy of pregabalin (PGB) in treatment of frequent nonconvulsive seizures
(NCS) and nonconvulsive status epilepticus (NCSE) in critically ill patients.
Methods: In this retrospective study, 21 patients were identiﬁed as having received pregabalin for the
treatment of NCS as determined by continuous electroencephalographic monitoring. The patients were
considered to be responders if their seizures were terminated within 24 h of initiation of PGB without the
addition of another antiepileptic agent.
Results: Of the 21 patients who received PGB for treatment of NCS or NCSE, 11 (52%) were responders.
PGB was administered via a nasogastric tube or orally and was the 2nd to 4th agent used. The average
initial dose and total daily dose of PGB was similar in the responders and non-responders (342 mg vs.
360 mg, respectively). PGB was more effective in aborting NCS (9 patients, 82%) than NCSE (2 patients,
18%). Of the 9 brain tumor patients, PGB resulted in seizure cessation in 67% (6 patients). In contrast, all
patients with hypoxic injury (4) did not respond to PGB. The responders were noted to have better
clinical outcome (64% vs. 9% discharged home). Most of the patients tolerated the medication without
any signiﬁcant short term adverse effects, except two patients who were noted to have dizziness and
sedation.
Conclusions: Pregabalin may be safe option for add-on treatment for nonconvulsive seizures in critically
ill patients when conventional therapy fails.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Nonconvulsive seizures (NCS) and nonconvulsive status epi-
lepticus (NCSE) are common in the neurologic intensive care unit
(NICU). Prior studies have documented that 10–48% of patients
admitted to medical or neurologic ICUs may be having frequent
NCS or be in NCSE.1
There are no prospective, randomized controlled trials evalu-
ating antiepileptic drugs (AEDs) for the treatment of NCS and NCSE.
Since more data is available for convulsive status epilepticus (CSE),
the treatment of NCS and NCSE has reﬂected that of CSE.
Benzodiazepines and phenytoin (PHT) are typical ﬁrst and
second-line treatments, respectively, to abort CSE.2 When these
fail, medications such as propofol, midazolam, phenobarbital, and
pentobarbital are often used.2 Due to central nervous system andAbbreviations: NCS, nonconvulsive seizures; NCSE, nonconvulsive status epilepti-
cus; NICU, neurologic intensive care unit; CSE, convulsive status epilepticus; AEDs,
antiepileptic drugs; PHT, phenytoin; PGB, pregabalin; LEV, levetiracetam; LAC,
lacosamide; cEEG, continuous electroencephalography.
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which can be associated with signiﬁcant morbidity.
Newer, non-sedating antiepileptic drugs (AEDs) such as
pregabalin (PGB),3,4 lacosamide,5 levetiracetam (LEV) and topir-
amate2 are being increasingly used in patients with NCS as
treatment is not deemed to be as urgent as in CSE. Non-sedating
AEDs are a particularly attractive alternative to older, sedating
AEDs as they avoid the complications (i.e. respiratory depression)
associated with sedating AEDs. The goal of this study was to
evaluate the efﬁcacy of PGB in NICU patients with NCSE and NCS.
2. Methods
This was a retrospective study in which patients aged greater
than or equal to 18 years of age admitted to the NICU at Duke
University Medical Center between August and December, 2007
who had received PGB were identiﬁed through inpatient pharmacy
records. Medical records of these patients were reviewed to
determine which patients underwent cEEG monitoring for NCS and
NCSE and received PGB for treatment. Previously described
deﬁnitions of NCS and NCSE are utilized at our institution.6–9 This
study was approved by the Institutional Review Board.
Demographic, clinical and cEEG data was reviewed for patients
who had received PGB for NCS and NCSE while undergoing cEEGvier Ltd. All rights reserved.
Table 1
Demographic information for patients that received pregabalin for the treatment of
NCS or NCSE.
Responders
(n = 11)
Non-responders
(n = 10)
p value
Average age (yrs) 50.9 60.6 0.09
Gender (male) (%) 5 (45.5) 7 (70) 0.69
Average PGB dose (mg) 342  49 360  54 0.80
Pre-existing epilepsy (%) 3 (27.3) 4 (40) 0.57
Table 2
Clinical outcomes and cEEG ﬁndings for patients that received pregabalin for the
treatment of NCS or NCSE.
Responders (n = 11) Non-responders (n = 10) p value
Outcome 0.06
Alive 9 (82%) 4 (40%)
Dead 2 (18%) 6 (60%)
cEEG ﬁndings 0.009
NCS 9 (82%) 2 (20%)
NCSE 2 (18%) 8 (80%)
C.B. Swisher et al. / Seizure 22 (2013) 116–118 117monitoring. Those patients whose electrographic seizure activity
stopped within 24 h of receiving PGB and did not return for at least
24 h were considered responders. Descriptive analysis was
obtained for the responder and nonresponder groups. Continuous
variables were compared using a two-tailed Student’s t-test, and
categorical variables were compared using a contingency analysis.
The Fisher exact statistic was used due to small sample size. A p
value of <0.05 was considered statistically signiﬁcant.
3. Results
A total of 51 patients were identiﬁed that received PGB while
admitted to the NICU. Of these, 21 patients received PGB for
treatment of NCS or NCSE while undergoing cEEG monitoring.
These patients formed the group that was further analyzed. The
remaining 30 patients had received PGB while in the NICU for
various pain syndromes (13 patients) and for prophylaxis of
seizures (17 patients). These latter 17 patients either did not
undergo cEEG monitoring or may have undergone cEEG monitor-
ing but did not have electrographic seizure activity and conse-
quently were not included in further analysis.
Of the 21 patients who received PGB for treatment of NCS and
NCSE, 11 (52%) had cessation of their electrographic seizure
activity (responders) and 10 (48%) did not (non-responders). The
demographic and clinical features for these 21 patients are
presented in Table 1. There was no signiﬁcant difference between
the two groups in terms of age, gender, and history of epilepsy.
Responders and non-responders received similar doses of PGB
(average daily dose of 342 mg vs. 360 mg, respectively).
Brain tumor patients were more likely to respond to PGB when
compared to patients with infection, hemorrhage, autoimmune
disease or hypoxia as the underlying etiology for their seizures. Of
the 9 brain tumor patients with NCS or NCSE, PGB resulted in
seizure cessation in 67% (6 patients). Conversely, all four patients
with hypoxic brain injury did not respond to PGB. The response
rates for various etiologies of NCS and NCSE are shown in Fig. 1.
PGB was administered via a nasogastric tube or orally. It was
administered as the 2nd agent in one patient and as the 3rd or 4thFig. 1. Graphical representation of NCSE and NCS agent in the rest. In the responder group, AEDs administered prior
to PGB include: LEV in 11 patients (average dose 2454  687 mg),
PHT in 7 patients (goal free PHT level 1.0–2.0), valproic acid in 1
patient, phenobarbital in 1 patient and midazolam infusion in 1
patient. In the non-responder group, AEDs administered prior to PGB
include: LEV in 10 patients (average dose 2600  966 mg), PHT in 6
patients (goal free PHT level 1.0–2.0), midazolam infusion in 7
patients, valproic acid in 2 patients, pentobarbital in 2 patients and
propofol in 1 patient. Most of the patients tolerated PGB without any
signiﬁcant short term adverse effects except two patients who were
noted to have dizziness and sedation.
CEEG monitoring revealed NCS in 11 patients and NCSE in 10
patients. Of the responders, 9 patients (82%) had NCS and 2
patients (18%) were noted to have NCSE (p = 0.009). Among the
non-responders, 2 patients (20%) had NCS and 8 patients (80%) had
NCSE (Table 2).
PGB responders were noted to have better clinical outcomes
(64% vs. 9% discharged home). The mortality rate of the non-
responders was high at 60% while the mortality rate of the
responders was much lower at 18% (p = 0.06) (see Table 2).
4. Discussion
In this retrospective study, PGB was found to be effective in
stopping NCS or NCSE in 52% of patients to whom it was
administered. This therapy was more effective in aborting NCS (9
patients, 82%) than NCSE (2 patients, 18%), which was statistically
signiﬁcant (p = 0.009). PGB was most effective in patients with
brain tumors and least effective in patients with hypoxic injury. In
brain tumor patients with NCS and NCSE, administration of PGB
resulted in seizure cessation in 67% while none of the four patients
with hypoxic injury had seizure cessation with PGB. This ﬁnding is
consistent with a recent retrospective study reported by our
institution that found that PGB added to PHT and LEV stopped
NCSE in 70% of brain tumor patients with refractory NCSE.3
PGB was well-tolerated and no major adverse events were
noted. Other studies using PGB,3,4 topirimate10,11 and LEV12
administered orally or via a nasogastric tube have also shown
efﬁcacy as add-on therapy for refractory NCS and NCSE. Theseetiology in patients that received pregabalin.
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necessary to treat NCSE or NCS. Furthermore, aggressive therapy
for NCS and NCSE may actually be detrimental. One study found
that elderly patients with NCSE who were treated with benzo-
diazepines had a higher mortality rate when compared to patients
treated less aggressively.13
Although PGB is only approved for use in the U.S. as adjunctive
therapy for patients with refractory partial seizures (and various
pain syndromes), it remains an attractive option for the treatment
of NCS and NCSE for several reasons. First, PGB can theoretically
complement other AEDs via its unique mechanism of action that
involves binding to and inhibition of the alpha-2-delta protein of
the presynaptic calcium channel. Second, PGB is not metabolized in
the liver and does not interact with other AEDs, which are
favorable characteristics of medications used in critically ill
patients. Lastly, PGB can be administered relatively quickly since
it lacks idiosyncratic side effects, has almost complete gastroin-
testinal absorption and reaches peak levels within 1 h.14
There are several limitations of this study. The results are
limited by the small sample size and retrospective design. In
addition, ideal loading and maintenance doses of PGB in this
setting have not been established. Lastly, the patients in this study
received at least one other AED before PGB, therefore one cannot be
certain which AED resulted in seizure cessation or if spontaneous
seizure cessation occurred. PGB was administered as the 3rd or 4th
AED in most patients, and seizure cessation may be attributed to a
delayed effect of the 1st or 2nd AED rather than PGB. A larger,
prospective study is warranted to determine the efﬁcacy and safety
of PGB in NCSE and NCS.
Despite the limitations of this study, our results suggest that
PGB can be considered as an alternative option for add-ontreatment of NCS and NCSE if standard therapy (i.e. benzodiaze-
pines and PHT) is unsuccessful.
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